DENTSPLY SIRONA (XRAY) to Release Quarterly Earnings on Tuesday

DENTSPLY SIRONA (NASDAQ:XRAY) is anticipated to issue its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect the company to announce earnings of $0.28 per share and revenue of $841.7680 million for the quarter. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 5, 2026 at 4:30 PM ET.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The company had revenue of $961.00 million for the quarter, compared to the consensus estimate of $926.40 million. During the same quarter in the prior year, the company earned $0.26 earnings per share. The company’s quarterly revenue was up 6.2% on a year-over-year basis. On average, analysts expect DENTSPLY SIRONA to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

DENTSPLY SIRONA Stock Up 0.5%

Shares of NASDAQ XRAY opened at $11.81 on Friday. DENTSPLY SIRONA has a 12 month low of $9.85 and a 12 month high of $17.18. The company has a current ratio of 1.51, a quick ratio of 1.03 and a debt-to-equity ratio of 1.50. The firm has a market capitalization of $2.37 billion, a price-to-earnings ratio of -3.94, a PEG ratio of 1.39 and a beta of 0.93. The business has a 50-day moving average of $12.16 and a 200-day moving average of $12.04.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on XRAY. Barrington Research boosted their price objective on DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an “outperform” rating in a report on Monday, March 2nd. Robert W. Baird upped their target price on DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a research note on Friday, February 27th. Zacks Research raised DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research note on Monday, March 2nd. Citigroup started coverage on DENTSPLY SIRONA in a research note on Wednesday, April 15th. They issued a “sell” rating and a $10.00 target price for the company. Finally, Wells Fargo & Company upped their target price on DENTSPLY SIRONA from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Friday, February 27th. Three analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, DENTSPLY SIRONA presently has a consensus rating of “Hold” and an average target price of $13.91.

Insider Activity at DENTSPLY SIRONA

In other news, Director Gregory T. Lucier acquired 15,000 shares of the firm’s stock in a transaction on Monday, March 9th. The stock was acquired at an average price of $12.45 per share, for a total transaction of $186,750.00. Following the completion of the acquisition, the director owned 65,000 shares in the company, valued at $809,250. This trade represents a 30.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director James D. Forbes acquired 5,000 shares of the firm’s stock in a transaction on Monday, March 9th. The stock was purchased at an average price of $12.48 per share, with a total value of $62,400.00. Following the acquisition, the director owned 10,000 shares of the company’s stock, valued at $124,800. This represents a 100.00% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders acquired 70,000 shares of company stock valued at $956,437. 0.50% of the stock is owned by insiders.

Hedge Funds Weigh In On DENTSPLY SIRONA

Several large investors have recently modified their holdings of XRAY. Sivia Capital Partners LLC bought a new stake in DENTSPLY SIRONA in the 2nd quarter worth about $389,000. NorthRock Partners LLC increased its holdings in DENTSPLY SIRONA by 36.7% in the 3rd quarter. NorthRock Partners LLC now owns 17,663 shares of the medical instruments supplier’s stock worth $224,000 after buying an additional 4,744 shares in the last quarter. Integrated Advisors Network LLC bought a new stake in DENTSPLY SIRONA in the 4th quarter worth about $205,000. EP Wealth Advisors LLC bought a new stake in shares of DENTSPLY SIRONA during the 4th quarter valued at about $161,000. Finally, Pitcairn Co. bought a new stake in shares of DENTSPLY SIRONA during the 2nd quarter valued at about $160,000. Hedge funds and other institutional investors own 95.70% of the company’s stock.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.